Most Recent Jobs
Post an Event
Microbix Biosystems Inc. is a
biotechnology company that is focused on leveraging its Core Base Business unit
that has commercialized over 60 products in the virology and cell culture
technologies in order to finance its more-lucrative large-market pipeline of
products. These include: Kinlytic
(Urokinase), VIRUSMAX™ (Virus Yield Enhancement Technology), and LumiSort™
(livestock sex selection technology). In
addition, the Company has established a JV in Hunan, China for the manufacture
and distribution of influenza vaccines using VIRUSMAX™ technology.
The Company announced Q3/2011
results ended June 30. These results are evidence of the Company's success
in its continued commitment and focus on improving earnings and operating cash
flow. With the Canadian
dollar having weakened somewhat over the past several weeks, we suspect
that Microbix will be able to maintain the improved operating performance through
the fourth quarter.
With strong growth opportunities in large markets,
Microbix is ready to make the breakthrough in realizing on its long-term
vision. We rate the shares a Speculative Buy and have a 12-months Target Price
of $1.15 per share. This price target is dependent upon the Company achieving
its strategic objectives.
To read the full commentary, click
eResearch is a primary source for
professional investment research, focused primarily on small- and mid-cap
companies. Our research and analysis is of institutional quality, and has the
potential for reaching millions of global investors through our extensive
electronic distribution network.
eResearch posts all its reports and
articles on its website, www.eresearch.ca, and
subscription is FREE.
To learn more about eResearch, click here: http://www.eresearch.ca/_pdfs/eResearchPPP.pdf.
eResearch: Bob Weir, CFA, Managing
Director, Research Services
(416) 703-6258 Ext 221; E-mail: email@example.com